Barry D. Quart
2014
In 2014, Barry D. Quart earned a total compensation of $3.9M as Chief Executive Officer at Heron Therapeutics, a 53% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $252,801 |
|---|---|
| Option Awards | $3,082,908 |
| Salary | $540,750 |
| Other | $7,800 |
| Total | $3,884,259 |
Quart received $3.1M in option awards, accounting for 79% of the total pay in 2014.
Quart also received $252.8K in non-equity incentive plan, $540.8K in salary and $7.8K in other compensation.
Rankings
In 2014, Barry D. Quart's compensation ranked 2,199th out of 13,032 executives tracked by ExecPay. In other words, Quart earned more than 83.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,199 out of 13,032 | 83rd |
Division Manufacturing | 782 out of 4,966 | 84th |
Major group Chemicals And Allied Products | 248 out of 1,686 | 85th |
Industry group Drugs | 192 out of 1,365 | 86th |
Industry Pharmaceutical Preparations | 158 out of 1,043 | 85th |
Source: SEC filing on April 29, 2016.
Quart's colleagues
We found three more compensation records of executives who worked with Barry D. Quart at Heron Therapeutics in 2014.
News
Heron Therapeutics CEO Craig Collard receives $11M in 2023
April 29, 2024
Heron Therapeutics Executive Vice President, Drug Development Kimberly Manhard's 2022 pay falls 22% to $1.4M
May 1, 2023
Heron Therapeutics CEO Barry Quart's 2021 pay rises 2% to $5.4M
April 25, 2022
Heron Therapeutics CEO Barry Quart's 2020 pay slips 9% to $5.3M
April 22, 2021
Heron Therapeutics CEO Barry Quart's 2019 pay slips 2% to $5.9M
April 23, 2020